Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > February 7, 2023
Daily News
February 7, 2023
- Eisai Alzheimer’s Chief Says Lecanemab US Sales “Ahead of Expectations”
February 7, 2023
- Next Astellas CEO Says Weathering Xtandi Cliff Is His Biggest Mission
February 7, 2023
- Teijin Pharma Picks R&D Chief Taneda for President from April
February 7, 2023
- Mochida Abandons Antidepressant MD-120, Lexapro’s Pediatric Use
February 7, 2023
- Astellas’ April-December Sales Up 17% on FX Tailwind; Xtandi Slows in US but Brisk in Japan
February 7, 2023
- Eisai’s 9-Month Profits Sink after One-Time BMS Alliance Gain a Year Ago
February 7, 2023
- Opdivo Extends Streak of Top-Seller Crown to 13 Months: Encise
February 7, 2023
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…